CureVac - Hauptforum Forum: Community User: NeulingImDAX

wann ist nochmal die diesjährige HV ?

Wer zu spät dran ist, denn bestraft das Leben....der Satz gilt auch hier. Mal sehen im Herbst. Ich bin mal eingestiegen.

Read SEC filings on data and cohort reports- as what media in Germany produce is diatribe and cynical political junk. Apologies- German media produces such political motivated rubbish at this time- it so hard to understand the German people accepting this rubbish Green onionskin comes to mind

https://www.google.de/amp/s/www.stuttgarter-nachrichten.de/inhalt.tuebinger-corona-impfstoff-curevac-hofft-auf-zulassung-bis-ende-juni.404731ae-7c46-4cf2-9182-7c482b12c580._amp.html hier steht auch das es aktuell 111 sind

Guten Morgen zusammen, M610, das war auch genau mein Gedanke... die Aussage, die nächste Stufe von 111. . noch im Juni... mhm 🤔

Jon 👍

Ich dachte auch das 111 schon erreicht sind

@rudi: die 15.000 waren auf die Placebo Gruppe runtergerechnet und wenn man die Infektionszahlen in Lateinamerika anschaut, denke ich auch, das die 160 in Kürze da sein sollen. Ich frage mich allerdings, warum in der Stellungnahme an Ännchen gesagt wird, dass die nächste Stufe bei 111 kommuniziert wird und andererseits Frau Fakih bereits in Presseinfos mitgeteilt hatte, dass man die 111 bereits hat. Nicht verkehrt verstehen, ich bin selbst mit einer für mich hohen Summe investiert, aber da ich momentan auch einen minus buchwert habe, beschäftigt mich das. Ich denke ja auch, dass die 111 wirklich schon längst da sind und frage mich, warum da noch keine info kommt. Kann das noch am sequenzieren liegen, was denkst du?

👍 wow - hört sich gut an Jonathan

jon, thx for that information

. A new group of vaccine makers is hoping to challenge the already well-known Covid-19 vaccinations, thereby increasing competition in the vaccine market, which is said to include the entire world population for the first time. But the global need for coronavirus vaccines is so great that the next phase of the pandemic offers other players the chance to enter the market. Large pharmaceutical companies like Sanofi and GSK hope to get rid of their image as laggards, while startups like Novavax, CureVac and Valneva see opportunities to meet the unmet need. The newcomers face special hurdles: new variants, which is dampening efficacy rates in clinical trials, manufacturing capacities being consumed by already-approved vaccines, and a public more inclined to trust the vaccines they know CureVac, the next round of vaccines could also have a third mRNA syringe on the Bring market. German biotech company CureVac believes its other formulation has advantages over Pfizer and Moderna vaccines. Because a much smaller dose is needed, the cost of production is relatively low and it might be easier to combine vaccines against different variants in a single syringe. CureVac scientists also believe that vaccination can produce a stronger response in the body's own T cells, which supplement the antibodies in the immune system, since no chemical changes are made to the mRNA. Pierre Kemula, CureVac's chief financial officer, believes these factors will be key selling points once the pandemic is better under control. "Lower dose, decent cost, broader mix of large, medium and small manufacturing solutions, and flexibility. It will be really interesting to see what this can bring to the world." But the size of the ability to provide doses for both primary and potential booster vaccinations makes it worthwhile. In fact, newcomer Novavax is forecast to overtake Moderna as the top-selling Covid-19 vaccine maker next year, with estimated sales of $ 27.9 billion in 2022, according to Airfinity, a London-based analytics firm. If their vaccines are approved, Airfinity predicts that Sanofi, GSK and CureVac will have sales of more than $ 9 billion in the next year - well above the $ 3 billion in annual sales that typically define a "blockbuster" drug. But some might have advantages, such as in the case of CureVac vaccination, that it is cheaper to produce and possibly easier to combine with other vaccines in a single syringe. J

Longstrong today 10:38 am --- The post is from US Based Motley fool- seeking alpha- its a promotion and re ramp to lower stock and motley fool are paid by pharma shares Pfizer - so you must tread carefully read disclosures. onvista are a low rate churning bin scrapper . If you want details see Friday post based on fact I made - not fiction

Ännchen, sorry: eigentlich nur was man auch im Header liest. Covid wird nie verschwinden, im Kontext zusammengefasst.

Onvista Artikel: immerhin schreiben Sie dass - wie auch CureVac selber - noch im zweiten Quartal mit den Daten gerechnet wird. Hoffe nächste Woche gibt es nicht wieder ständig den Spahn-Lucha-Eintopf 😅

Moin Allerseits ☀️ @Long: den Artikel von Rheinpfalz kann man nur mit Abo öffnen… steht was spannendes drin?

https://www.onvista.de/news/curevac-aktie-die-impfstoffeinfuehrung-entwickelt-sich-zum-albtraum-463805807